Rani Therapeutics Holdings, Inc. Stock Analysis & AI Score
Rani Therapeutics Holdings, Inc. (RANI) has an ST Score of 49.9 (C+), driven by its Forecast (A) and held back by its Profitability (D+). Analysts rate it Buy with a $15.67 price target (+2037.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIRANI Stock Price History
RANI Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
RANI Latest Stock News
ST Score
Rani Therapeutics Holdings, Inc. (RANI) has an ST Score of 49.9 (C+), driven by its Forecast (A) and held back by its Profitability (D+). Analysts rate it Buy with a $15.67 price target (+2037.2% upside).
- Strongest
- ForecastA
- Weakest
- ProfitabilityD+
All factor grades
- ForecastA
- MomentumB-
- GrowthB-
- ValuationC
- Financial StrengthC-
- ProfitabilityD+
- Piotroski5/9
Press Releases
Company Contact Details
RANI stock: frequently asked questions
What is RANI's ST Score?
Rani Therapeutics Holdings, Inc. (RANI) has an ST Score of 49.9 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RANI a buy, hold, or sell?
Analysts rate RANI a Buy, with a price target of $15.67 (+2037.2% vs the current price). Our ST Score grades it C+ (49.9/100). The ST Score is a data-driven signal, not a recommendation.
What are RANI's factor grades?
Valuation C, Profitability D+, Financial Strength C-, Momentum B-, Growth B-, Forecast A.
What is RANI's valuation grade?
Rani Therapeutics Holdings, Inc. (RANI) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RANI's growth grade?
Rani Therapeutics Holdings, Inc. (RANI) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RANI's profitability grade?
Rani Therapeutics Holdings, Inc. (RANI) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RANI's financial strength grade?
Rani Therapeutics Holdings, Inc. (RANI) earns a financial strength grade of C-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for RANI?
The average analyst price target for Rani Therapeutics Holdings, Inc. (RANI) is $15.67 from 7 analysts, which is +2037.2% versus the recent price of $0.73.
What is RANI's Piotroski score?
Rani Therapeutics Holdings, Inc. (RANI) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.